(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

"Mainz Biomed partners with Quest for colorectal cancer screening test" was originally created and published by Medical ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

Mainz Biomed has announced a partnership with Quest Diagnostics ... The test leverages polymerase chain reaction (PCR) technology to detect cancerous DNA in stool samples and is poised to enhance ...

Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool ...

announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz Biomed’s NextGen screening test for ...

Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal ... “We are excited by the opportunity to work with Quest Diagnostics,” commented Guido Baechler, Chief Executive ...